ANG Lifesciences India Ltd. IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| NII (HNI) | — | 712,000 (47%) | — | ₹570 Cr |
| Retail | — | 712,000 (47%) | — | ₹570 Cr |
| Market Maker | — | 76,800 (5%) | — | ₹6 Cr |
| Σ Total | — | 1,500,800 (100%) | — | ₹12,006 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 1,600 | ₹128,000 |
| Retail (Max) | 13 | 20,800 | ₹1,664,000 |
| S-HNI (Min) | 14 | 22,400 | ₹1,792,000 |
| B-HNI (Min) | 67 | 107,200 | ₹8,576,000 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- To meet the working capital requirement – 11.64
- To meet the Issue Expenses – 0.37
Company Overview
Incorporated in 2006, ANG Lifesciences India Limited is a pharmaceutical company whose engaged in the business of manufactures and markets finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials in India.
Company's products include sterile dry powder vials for anti-biotics, anti-ulcerant, glucocorticoid and anti-inflammatory, anti-malarial, and anesthetic. It manufactures products in compliance with GMP requirements.
However, Company that currently operates at an average capacity utilization of 70% for last two fiscals hopes to achieve 90% plus in coming years. ANGL is likely to consider acquisition options as well to enhance its manufacturing capacities. Its customer list includes Wockhardt, DHS Maharashtra, Global Hospitals, Elder, Emcure, BPPI, Govt. of Haryana, Hetero Healthcare etc.